Stock ABUS ARBUTUS BIOPHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
2.73 USD +0.37% Intraday chart for Arbutus Biopharma Corporation +0.37% +9.20%
04-05 Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT
04-04 Moderna Suffers Setback in Lawsuit by Arbutus MT

Evolution of the average Target Price on Arbutus Biopharma Corporation

Price target over the last 5 years

History of analyst recommendation changes

35c0ff89f310f437ecbb58acbfa78841.Pyv-YXRYcv-nCTHpPRWfdfs0GlnWARgU50EKtW6qJus.ClzPVQU8KLLRRWPZeG-rJJxOLzGdYitf1S5P_SDGS5wSeIsQMisBrNckaA~f2a5fdfb3b492ea46168f0034c48e8bf

Analyst Recommendations on Arbutus Biopharma Corporation

HC Wainwright Trims Price Target on Arbutus Biopharma to $5 From $6, Keeps Buy Rating MT
JMP Securities Adjusts Arbutus Biopharma Price Target to $4 From $6, Maintains Market Outperform Rating MT
HC Wainwright Adjusts Price Target on Arbutus Biopharma to $6 From $7.50, Maintains Buy Rating MT
JMP Securities Adjusts Arbutus Biopharma Price Target to $9 From $10, Maintains Market Outperform Rating MT
HC Wainwright Adjusts Arbutus Biopharma's Price Target to $8.50 From $8, Maintains Buy Rating MT
Chardan Research Adjusts Arbutus Biopharma's Price Target to $6 From $5.50; Buy Rating Kept MT
Jefferies Upgrades Arbutus Biopharma to Buy From Hold, Adjusts Price Target to $5 From $4 MT
HC Wainwright Adjusts Arbutus Biopharma PT to $8 From $10, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Arbutus Biopharma to $9 From $7, Maintains Market Outperform Rating MT
ARBUTUS BIOPHARMA : Wedbush Adjusts Price Target on Arbutus Biopharma to $6 From $7, Keeps Outperform Rating MT
ARBUTUS BIOPHARMA : Jefferies Starts Arbutus Biopharma at Hold With $5 Price Target MT
ARBUTUS BIOPHARMA : HC Wainwright Starts Arbutus Biopharma at Buy With $10 Price Target MT
ARBUTUS BIOPHARMA : Wedbush Adjusts Arbutus Biopharma's Price Target to $7 From $5 Following Updated AB-729 Data, Keeps at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.737 CAD
Average target price
5.962 CAD
Spread / Average Target
+59.53%
High Price Target
6.786 CAD
Spread / Highest target
+81.58%
Low Price Target
5.407 CAD
Spread / Lowest Target
+44.68%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Arbutus Biopharma Corporation

HC Wainwright
JMP Securities
Chardan Research
Jefferies & Co.

Ratings for Arbutus Biopharma Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ABUS Stock
  4. Consensus Arbutus Biopharma Corporation